Invitro findings were corroborated in an invivo CLD model, wherein sEVsApo ameliorated fibrosis and inflammation, by inhibiting TGF-β/ SMAD2/3 pathway. This evidence concerns the gene SMAD2 and congenital secretory chloride diarrhea 1.